Beta Bionics, Inc.
No enriched coverage for $BBNX in the last 7 days.
No SEC Form 4 filings for $BBNX in the last 30 days.
Beta Bionics reported Q2 2026 revenue of $32M and gross margin of 59%, up from 54% a year earlier, while posting a wider-than-expected adjusted loss of 53 cents per share. The company reaffirmed full-year 2026 revenue guidance of $131M to $136M and raised gross margin guidance to 58.5% to 59.5%.
Beta Bionics reported Q2 2026 EPS of -$0.53, worse than analysts’ -$0.34, on revenue of $32M, up 38% year over year. Gross margin improved to 59.0%. The company reaffirmed full-year revenue guidance of $131M-$136M and raised gross margin guidance to 58.5%-59.5%. Shares fell 4.18% to $15.14, then rose 2.18% after hours.
Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.
Recent BBNX coverage spans earnings, insider activity and market movers.
Beta Bionics reported Q2 2026 revenue of $32M and gross margin of 59%, up from 54% a year earlier, while posting a wider-than-expected adjusted loss of 53 cents per share. The company reaffirmed full-year 2026 revenue guidance of $131M to $136M and raised gross margin guidance to 58.5% to 59.5%.
Beta Bionics reported Q2 2026 EPS of -$0.53, worse than analysts’ -$0.34, on revenue of $32M, up 38% year over year. Gross margin improved to 59.0%. The company reaffirmed full-year revenue guidance of $131M-$136M and raised gross margin guidance to 58.5%-59.5%. Shares fell 4.18% to $15.14, then rose 2.18% after hours.
Q2 beat plus reaffirmed 2026 revenue and gross margin range can support near-term sentiment, but patient-start and sequential iLet trends temper optimism.
Sales growth is being offset by ongoing operating losses and a quality-system Warning Letter, raising near-term regulatory and execution risk.
Guidance and channel mix updates (notably PBP growth) plus ongoing losses and cash runway are the key near-term drivers for BBNX positioning.
alphai scores every news story that mentions BBNX with an AI model for sentiment and relevance, and aggregates insider trades from Beta Bionics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Beta Bionics reported Q2 2026 revenue of $32M and gross margin of 59%, up from 54% a year earlier, while posting a wider-than-expected adjusted loss of 53 cents per share. The company reaffirmed full-year 2026 revenue guidance of $131M to $136M and raised gross margin guidance to 58.5% to 59.5%.
5 min readBeta Bionics reported Q2 2026 EPS of -$0.53, worse than analysts’ -$0.34, on revenue of $32M, up 38% year over year. Gross margin improved to 59.0%. The company reaffirmed full-year revenue guidance of $131M-$136M and raised gross margin guidance to 58.5%-59.5%. Shares fell 4.18% to $15.14, then rose 2.18% after hours.
6 min readBeta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.
4 min readBeta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.
4 min readBeta Bionics, Inc. (BBNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the developmen
6 min readBeta Bionics, Inc. disclosed in a Schedule 13G that Divisadero Street Capital Management, LP and William Zolezzi report beneficial ownership of 3,072,985 shares, or 6.9% of the common stock. Divisadero Street Partners, L.P. and its GP report 2,612,985 shares, or 5.9%. The filing shows only shared voting and dispositive power.
2 min readBeta Bionics, Inc. (Nasdaq: BBNX) said it will report second-quarter 2026 financial results after market close on July 29, 2026. Management plans a conference call and webcast the same day at 4:30 pm ET to review performance. The webcast link will be posted on the company’s investor site.
2 min readHopman Mark (Chief Commercial Officer) sold 275 shares of Beta Bionics, Inc. (BBNX) at $12.31 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readJones Christy sold 2,811 shares of Beta Bionics, Inc. (BBNX) at $14.00 on 2026-06-04 under a Rule 10b5-1 trading plan.
1 min readMensinger Mike (Chief Product Officer) sold 4,378 shares of Beta Bionics, Inc. (BBNX) at $12.61 on 2026-06-02.
2 min read
